Positive News SentimentPositive NewsNASDAQ:ALGS Aligos Therapeutics (ALGS) Stock Forecast, Price & News $0.71 -0.02 (-2.74%) (As of 02:27 PM ET) Add Compare Share Share Today's Range$0.70▼$0.7650-Day Range$0.73▼$1.0052-Week Range$0.70▼$2.41Volume16,978 shsAverage Volume223,990 shsMarket Capitalization$30.89 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Aligos Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside440.5% Upside$4.00 Price TargetShort InterestBearish2.86% of Float Sold ShortDividend StrengthN/ASustainability-0.80Upright™ Environmental ScoreNews Sentiment1.57Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.83) to ($1.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.44 out of 5 starsMedical Sector178th out of 963 stocksBiological Products, Except Diagnostic Industry25th out of 159 stocks 3.3 Analyst's Opinion Consensus RatingAligos Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Aligos Therapeutics has a forecasted upside of 440.5% from its current price of $0.74.Amount of Analyst CoverageAligos Therapeutics has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted2.86% of the float of Aligos Therapeutics has been sold short.Short Interest Ratio / Days to CoverAligos Therapeutics has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Aligos Therapeutics has recently increased by 0.55%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAligos Therapeutics does not currently pay a dividend.Dividend GrowthAligos Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAligos Therapeutics has received a 76.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services of the circulatory system", "Clinical research services for metabolic diseases", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Aligos Therapeutics is -0.80. Previous Next 3.6 News and Social Media Coverage News SentimentAligos Therapeutics has a news sentiment score of 1.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aligos Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ALGS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Aligos Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aligos Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.50% of the stock of Aligos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions60.43% of the stock of Aligos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aligos Therapeutics are expected to grow in the coming year, from ($1.83) to ($1.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aligos Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aligos Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAligos Therapeutics has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aligos Therapeutics (NASDAQ:ALGS) StockAligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009, a small molecule THR-ß agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition, it develops siRNA drug candidate, ALG-125755, which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics, Inc. has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH, as well as a research collaboration and development agreement with Xiamen Amoytop Biotech Co., Ltd. to research and develop oligonucleotide compounds for the treatment of liver diseases.. The company was incorporated in 2018 and is headquartered in South San Francisco, California.Read More ALGS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALGS Stock News HeadlinesSeptember 21, 2023 | finance.yahoo.comAligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009August 20, 2023 | fool.comAligos Therapeutics (NASDAQ: ALGS)September 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. August 3, 2023 | msn.comAligos Therapeutics GAAP EPS of -$0.43 beats by $0.06, revenue of $2.59MAugust 3, 2023 | finance.yahoo.comAligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial ResultsAugust 3, 2023 | finance.yahoo.comAligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial ResultsJuly 28, 2023 | finance.yahoo.comAligos Therapeutics to Announce Second Quarter Results on August 03, 2023July 19, 2023 | finance.yahoo.comAligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009September 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."June 21, 2023 | finance.yahoo.comAligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023June 7, 2023 | it.tmcnet.comAligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023May 24, 2023 | finance.yahoo.comAligos Therapeutics to Present at the Jefferies 2023 Healthcare ConferenceMay 15, 2023 | msn.comAligos Therapeutics and Xiamen Amoytop Biotech join hands for the treatment of liver diseasesMay 12, 2023 | finance.yahoo.comAligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver DiseasesMay 5, 2023 | markets.businessinsider.comSVB Securities Remains a Hold on Aligos Therapeutics (ALGS)May 5, 2023 | finance.yahoo.comAligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue EstimatesMay 4, 2023 | msn.comRecap: Aligos Therapeutics Q1 EarningsMay 4, 2023 | benzinga.comAligos Therapeutics Stock (NASDAQ:ALGS), DividendsApril 27, 2023 | finance.yahoo.comAligos Therapeutics to Announce First Quarter Results on May 4, 2023April 17, 2023 | finance.yahoo.comAligos Therapeutics, Inc.'s (NASDAQ:ALGS) 30% Dip In Price Shows Sentiment Is Matching RevenuesApril 11, 2023 | tmcnet.comAligos Therapeutics to Present Data from Chronic HepatitisApril 11, 2023 | finance.yahoo.comAligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023March 29, 2023 | finance.yahoo.comAligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology ConferenceMarch 14, 2023 | msn.comAligos Therapeutics Earnings Perspective: Return On Capital EmployedMarch 9, 2023 | finance.yahoo.comAligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue EstimatesMarch 9, 2023 | finance.yahoo.comAligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial ResultsMarch 9, 2023 | finance.yahoo.comAligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial ResultsSee More Headlines Receive ALGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALGS Company Calendar Last Earnings8/03/2023Today9/27/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALGS CUSIPN/A CIK1799448 Webwww.aligos.com Phone800-466-6059FaxN/AEmployees68Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$7.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+447.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,050,000.00 Net Margins-476.77% Pretax Margin-472.13% Return on Equity-86.51% Return on Assets-61.08% Debt Debt-to-Equity RatioN/A Current Ratio3.46 Quick Ratio3.46 Sales & Book Value Annual Sales$13.91 million Price / Sales2.28 Cash FlowN/A Price / Cash FlowN/A Book Value$2.42 per share Price / Book0.30Miscellaneous Outstanding Shares43,500,000Free Float36,325,000Market Cap$31.76 million OptionableNot Optionable Beta2.19 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Lawrence M. Blatt MBA (Age 61)Ph.D., CEO & Chairman Comp: $832.73kDr. Leonid Beigelman Ph.D. (Age 64)Pres & Director Comp: $664.43kDr. Julian A. Symons DPHIL (Age 62)Exec. VP & Chief Scientific Officer Comp: $618.66kMs. Lesley Ann Calhoun CPA (Age 57)Exec. VP & CFO Ms. Lucinda Y. Quan J.D. (Age 51)Exec. VP, Chief Bus. Officer & Gen. Counsel Kristina EngesethVP and Head of People & CultureDr. Matthew W. McClure M.D. (Age 51)Exec. VP & Chief Medical Officer Dr. Sushmita M. Chanda DABT (Age 57)Ph.D., Exec. VP of Translational Safety Sciences Dr. David B. Smith Ph.D.Exec. VP & Head of Chemical OperationsDr. Tse-I Lin Ph.D.VP of Early Compound Devel. & Belgian Site HeadMore ExecutivesKey CompetitorsElevation OncologyNASDAQ:ELEVCandel TherapeuticsNASDAQ:CADLCASI PharmaceuticalsNASDAQ:CASICyclo TherapeuticsNASDAQ:CYTHCortexymeNASDAQ:CRTXView All CompetitorsInstitutional OwnershipRoyal Bank of CanadaBought 795,678 shares on 8/15/2023Ownership: 1.932%Renaissance Technologies LLCSold 22,305 shares on 8/11/2023Ownership: 1.003%Geode Capital Management LLCBought 56,734 shares on 8/11/2023Ownership: 0.598%Charles Schwab Investment Management Inc.Bought 31,383 shares on 8/10/2023Ownership: 0.073%View All Institutional Transactions ALGS Stock - Frequently Asked Questions Should I buy or sell Aligos Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aligos Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALGS shares. View ALGS analyst ratings or view top-rated stocks. What is Aligos Therapeutics' stock price forecast for 2023? 3 Wall Street research analysts have issued 12-month price targets for Aligos Therapeutics' shares. Their ALGS share price forecasts range from $2.00 to $7.00. On average, they expect the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 447.9% from the stock's current price. View analysts price targets for ALGS or view top-rated stocks among Wall Street analysts. How have ALGS shares performed in 2023? Aligos Therapeutics' stock was trading at $0.9529 at the beginning of the year. Since then, ALGS stock has decreased by 23.4% and is now trading at $0.73. View the best growth stocks for 2023 here. When is Aligos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our ALGS earnings forecast. How were Aligos Therapeutics' earnings last quarter? Aligos Therapeutics, Inc. (NASDAQ:ALGS) issued its earnings results on Thursday, August, 3rd. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.07. The firm earned $6.89 million during the quarter. Aligos Therapeutics had a negative net margin of 476.77% and a negative trailing twelve-month return on equity of 86.51%. When did Aligos Therapeutics IPO? (ALGS) raised $150 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO and Cantor was co-manager. What is Aligos Therapeutics' stock symbol? Aligos Therapeutics trades on the NASDAQ under the ticker symbol "ALGS." Who are Aligos Therapeutics' major shareholders? Aligos Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Royal Bank of Canada (1.93%), Renaissance Technologies LLC (1.00%), Geode Capital Management LLC (0.60%) and Charles Schwab Investment Management Inc. (0.07%). Insiders that own company stock include Thomas Woiwode and Vivo Capital Fund Viii, LP. View institutional ownership trends. How do I buy shares of Aligos Therapeutics? Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aligos Therapeutics' stock price today? One share of ALGS stock can currently be purchased for approximately $0.73. How much money does Aligos Therapeutics make? Aligos Therapeutics (NASDAQ:ALGS) has a market capitalization of $31.76 million and generates $13.91 million in revenue each year. The company earns $-96,050,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. How can I contact Aligos Therapeutics? The official website for the company is www.aligos.com. The company can be reached via phone at 800-466-6059 or via email at cdavis@lifesciadvisors.com. This page (NASDAQ:ALGS) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.